Barclays PLC Curis Inc Transaction History

Barclays PLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.71 - $2.43 $10,208 - $34,938	-14,378 Reduced 4.57%	300,000 $295,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $21,224 - $47,134	9,188 Added 3.01%	314,378 $749,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $641,218 - $1.17 Million	144,094 Added 89.45%	305,190 $1.45 Million
Q3 2021 Nov 09, 2021	BUY	$6.94 - $8.85 $48,822 - $62,259	7,035 Added 4.57%	161,096 $1.26 Million
Q2 2021 Aug 13, 2021	BUY	$7.45 - $16.27 $601,609 - $1.31 Million	80,753 Added 110.16%	154,061 $1.24 Million
Q1 2021 May 13, 2021	BUY	$8.78 - $12.8 $355,897 - $518,848	40,535 Added 123.68%	73,308 $830,000
Q4 2020 Feb 11, 2021	BUY	$1.08 - $8.2 $35,389 - $268,697	32,768 Added 655360.0%	32,773 $268,000
Q2 2020 Aug 12, 2020	SELL	$0.63 - $1.7 $6 - $17	-10 Reduced 66.67%	5 $0
Q1 2020 May 13, 2020	SELL	$0.67 - $1.85 $10 - $29	-16 Reduced 51.61%	15 $0
Q4 2019 Feb 10, 2020	SELL	$1.36 - $2.44 $164 - $295	-121 Reduced 79.61%	31 $0
Q1 2019 May 15, 2019	BUY	$0.78 - $2.01 $28 - $74	37 Added 32.17%	152 $0
Q4 2018 Feb 14, 2019	SELL	$0.62 - $2.25 $10 - $38	-17 Reduced 12.88%	115 $0
Q3 2018 Nov 14, 2018	SELL	$1.38 - $1.94 $54,242 - $76,253	-39,306 Reduced 99.67%	132 $0
Q2 2018 Aug 14, 2018	BUY	$1.73 - $3.35 $68,227 - $132,117	39,438 New	39,438 $68,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.